Healthcare Professionals
Lumivascular technology is radically changing the way vascular disease is treated. Through the CONNECT II and VISION trial, we were able to receive FDA clearance on both our CTO crossing catheter (Ocelot) and atherectomy catheter (Pantheris). Being able to see inside the artery with Optical Coherence Tomography (OCT) while performing the procedure is a real game changer. It allows the operator to make informed decisions for long term results while leaving normal arterial layers behind.
See Case StudiesClinical trials prove safety.
Gathering information through seeing inside the artery while performing the procedure may allow for better long term outcomes when you don’t disturb healthy layers of the artery. The data below shows the importance of visualization inside the artery.
vision ide 6 month
lumivascular ATHERECTOMY
130 PATIENTS | 20 SITES | 164 LESIONS | PRIMARY COHORT
LUMINAL GAIN | 72%
-
PRE-STENOSIS
-
PANTHERIS STANDALONE
-
POST-PANTHERIS +/- ADJUNCTIVE THERAPY
adventitia analysis
EFFICACY
Safety
follow-up data
lumivascular ATHERECTOMY
freedom from tlr
SOURCE: VISION (FULL COHORT, BY LESION)
-
12 MONTH (N=89)
-
18 MONTH (N=79)
-
24 MONTH (N=72)
FREEDOM FROM TLR & PRIMARY PATENCY*
SOURCE: EUROPEAN CASE SERIES (GRAZ, AUSTRIA) BY LESION
-
FREEDOM FROM TLR (12 MONTH) (N=33)
-
PRIMARY PATENCY (12 MONTH) (N=33)
* Patency is defined as PSVR < 2.4
CONNECT II DATA
LUMIVASCULAR CTO CROSSING
100 PATIENTS | 14 SITES | 100 LESIONS
LUMINAL CROSSING
-
93% = TRUE LUMEN
-
7% - SUBINTIMAL
Case Studies
View cases performed by your peers and colleagues in lesions below the knee, above the knee, CTOs, and more. These cases help show how Ocelot and Pantheris are changing the way operators see and perform procedures.
view case studiesEvents with Avinger
Visit Avinger at the following upcoming events to learn more on how Lumivascular is radically changing the way vascular disease is treated.
